These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 10915034)

  • 1. Reporting of adverse drug reactions by poison control centres in the US.
    Chyka PA; McCommon SW
    Drug Saf; 2000 Jul; 23(1):87-93. PubMed ID: 10915034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of US poison centers in adverse drug reactions monitoring.
    Chyka PA
    Vet Hum Toxicol; 1999 Dec; 41(6):400-2. PubMed ID: 10592954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events related to medications identified by a Canadian poison centre.
    Ackroyd-Stolarz SA; MacKinnon NJ; Murphy N; Gillespie E; Zed PJ
    J Popul Ther Clin Pharmacol; 2011; 18(2):e250-6. PubMed ID: 21576730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The state of dietary supplement adverse event reporting in the United States.
    Gardiner P; Sarma DN; Low Dog T; Barrett ML; Chavez ML; Ko R; Mahady GB; Marles RJ; Pellicore LS; Giancaspro GI
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):962-70. PubMed ID: 18613260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug identification: a survey of poison control centers.
    Jaramillo JE; Anderson HG; Jaramillo JP; Nester ML; Shum S
    J Toxicol Clin Toxicol; 2004; 42(4):371-81. PubMed ID: 15461245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the reporting of adverse drug reactions in the hospital setting.
    Pushkin R; Frassetto L; Tsourounis C; Segal ES; Kim S
    Postgrad Med; 2010 Nov; 122(6):154-64. PubMed ID: 21084792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeinated energy drinks: adverse event reports to the US Food and Drug Administration and the National Poison Data System, 2008 to 2015.
    Markon AO; Jones OE; Punzalan CM; Lurie P; Wolpert B
    Public Health Nutr; 2019 Oct; 22(14):2531-2542. PubMed ID: 31317857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting of adverse events to MedWatch.
    Piazza-Hepp TD; Kennedy DL
    Am J Health Syst Pharm; 1995 Jul; 52(13):1436-9. PubMed ID: 7671043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of adverse drug experience reports submitted by pharmacists and physicians to the FDA.
    Ahmad SR; Freiman JP; Graham DJ; Nelson RC
    Pharmacoepidemiol Drug Saf; 1996 Jan; 5(1):1-7. PubMed ID: 15088271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TESS database. Use in product safety assessment.
    Litovitz T
    Drug Saf; 1998 Jan; 18(1):9-19. PubMed ID: 9466085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014.
    Moore TJ; Furberg CD; Mattison DR; Cohen MR
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):713-8. PubMed ID: 26861066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the quality of adverse drug reaction reporting by 4th-year medical students.
    Rosebraugh CJ; Tsong Y; Zhou F; Chen M; Mackey AC; Flowers C; Toyer D; Flockhart DA; Honig PK
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):97-101. PubMed ID: 12642973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Texas pharmacists' opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study.
    Gavaza P; Brown CM; Khoza S
    Pharm World Sci; 2010 Oct; 32(5):651-7. PubMed ID: 20652830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of matching vaccine adverse event reporting system and poison center records.
    Forrester MB
    J Registry Manag; 2013; 40(2):93-7. PubMed ID: 24002134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of pharmacists' intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior.
    Gavaza P; Brown CM; Lawson KA; Rascati KL; Wilson JP; Steinhardt M
    Res Social Adm Pharm; 2011 Dec; 7(4):369-82. PubMed ID: 21272531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How many deaths occur annually from adverse drug reactions in the United States?
    Chyka PA
    Am J Med; 2000 Aug; 109(2):122-30. PubMed ID: 10967153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
    Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
    J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of internal reporting criteria on suspected adverse drug reactions submitted to MedWatch.
    Smith KM; Lawson AP; Tuteja S
    Am J Health Syst Pharm; 2006 May; 63(10):949-52. PubMed ID: 16675652
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of US poison centers: a 1998 survey conducted by the American Association of Poison Control Centers.
    Youniss J; Litovitz T; Villanueva P
    Vet Hum Toxicol; 2000 Feb; 42(1):43-53. PubMed ID: 10670088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.